NCT02354170View on ClinicalTrials.gov

Short-Term Oral Mifepristone for Central Serous Chorioretinopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 27, 2017

Study Completion Date

April 27, 2017

Conditions
Central Serous Chorioretinopathy
Interventions
DRUG

Mifepristone

DRUG

Placebo

Trial Locations (2)

94598

Bay Area Retina Associates, Walnut Creek

02114

Ophthalmic Consultants of Boston, Boston

All Listed Sponsors
collaborator

Ophthalmic Consultants of Boston

OTHER

lead

Roger Goldberg, M.D., MBA

OTHER

NCT02354170 - Short-Term Oral Mifepristone for Central Serous Chorioretinopathy | Biotech Hunter | Biotech Hunter